Can Regeneron Hit $540?
June 30, 2017 at 09:25 AM EDT
Down amid the recent biotech selloff, this drug maker's current share price is a call option on some important clinical trials and an under-appreciated cancer pipeline.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|